| NCCN guidelines insights: antiemesis, version 2.2017 MJ Berger, DS Ettinger, J Aston, S Barbour, J Bergsbaken, PJ Bierman, ... Journal of the National Comprehensive Cancer Network 15 (7), 883-893, 2017 | 231 | 2017 |
| Automated parenteral chemotherapy dose-banding to improve patient safety and decrease drug costs OG Fahey, SM Koth, JJ Bergsbaken, HA Jones, PJ Trapskin Journal of Oncology Pharmacy Practice 26 (2), 345-350, 2020 | 23 | 2020 |
| Initiatives to improve safety of oral anticancer agents delivered by community pharmacists K Meier, J Bergsbaken, S Suzuki European Medical Journal 3 (20), 60-68, 2018 | 22 | 2018 |
| PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost ER Hennes, EN Dow-Hillgartner, JJ Bergsbaken, JK Piccolo Journal of Oncology Pharmacy Practice 26 (3), 718-729, 2020 | 21 | 2020 |
| Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function M Fermiano, J Bergsbaken, JM Kolesar American journal of health-system pharmacy 71 (10), 793-798, 2014 | 20 | 2014 |
| Multidisciplinary optimization of oral chemotherapy delivery at the University of Wisconsin Carbone Cancer Center DL Mulkerin, JJ Bergsbaken, JA Fischer, MJ Mulkerin, AM Bohler, ... Journal of Oncology Practice 12 (10), e912-e923, 2016 | 19 | 2016 |
| Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities CE Renna, EN Dow, JJ Bergsbaken, TA Leal Journal of Oncology Pharmacy Practice 25 (4), 954-960, 2019 | 16 | 2019 |
| Assessment of adherence with oral anticancer agents in oncology clinical trials: a systematic review JJ Bergsbaken, JC Eickhoff, BA Buss, MS Mably, JM Kolesar Journal of Oncology Pharmacy Practice 22 (1), 105-113, 2016 | 15 | 2016 |
| Medication safety pharmacy technician in a large, tertiary care, community hospital KN Brown, J Bergsbaken, JS Reichard American Journal of Health-System Pharmacy 73 (4), 188-191, 2016 | 10 | 2016 |
| Antiemesis, version 2.2017 featured updates to the NCCN guidelines MJ Berger, DS Ettinger, J Aston, S Barbour, J Bergsbaken, PJ Bierman, ... JNCCN Journal of the National Comprehensive Cancer Network 15 (7), 883-893, 2017 | 8 | 2017 |
| Pharmacist participation in infection prevention: an innovative approach to monitoring compliance with the Five Moments for Hand Hygiene in a large academic medical center J Bergsbaken, LT Schulz, PJ Trapskin, J Marx, N Safdar American journal of infection control 42 (3), 331-332, 2014 | 8 | 2014 |
| Implementation of a clinical pharmacist-led service to optimize management of refractory chemotherapy-induced nausea and vomiting in adult hematology/oncology clinic CS Quinn, JJ Bergsbaken, EJ Blessinger, JK Piccolo Journal of Oncology Pharmacy Practice 28 (7), 1499-1507, 2022 | 7 | 2022 |
| Unleashing the power of immunotherapy and targeted therapy combinations: Advancing cancer care or discovering unknown toxicities? DJ Przybylski, JJ Bergsbaken, JK Piccolo Journal of Oncology Pharmacy Practice 27 (4), 930-938, 2021 | 7 | 2021 |
| Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation KH Peh, DJ Przybylski, MJ Fallon, JJ Bergsbaken, PR Hutson, M Yu, ... Journal of Oncology Pharmacy Practice 29 (5), 1094-1102, 2023 | 5 | 2023 |
| ASHP-HOPA guidelines on the roles and responsibilities of the pharmacy technician in ambulatory oncology pharmacy J Bergsbaken, D Roman, MA Earl, A McBride, JL Olin, A Peele, ... American Journal of Health-System Pharmacy 75 (17), 1304-1311, 2018 | 5 | 2018 |
| Implementing value assessment in oncology practice: a single-center experience K Saunders, MS Mably, SS Shull, H Jones, TA Leal, JJ Bergsbaken Journal of Oncology Pharmacy Practice 25 (4), 947-953, 2019 | 4 | 2019 |
| Hypertension and QT interval prolongation associated with targeted systemic cancer therapies OG Fahey, JK Piccolo, JJ Bergsbaken, E N Dow-Hillgartner Journal of Oncology Pharmacy Practice 26 (8), 1987-1996, 2020 | 1 | 2020 |
| Implementation of a chemotherapy stewardship process ER Hennes, M Reed, M Mably, J Jared, JJ Bergsbaken, D Deming, ... American Journal of Health-System Pharmacy 77 (15), 1243-1248, 2020 | 1 | 2020 |
| P-237 Bendamustine (B) is associated with low response rates in heavily pretreated relapsed refractory multiple myeloma (RRMM) Z Gahvari, T Schmidt, M Brunner, J Bergsbaken, N Callander Clinical Lymphoma Myeloma and Leukemia 23, S166, 2023 | | 2023 |
| A quality improvement project to implement oral anticoagulant thromboprophylaxis in ambulatory gynecologic cancer patients undergoing chemotherapy (162) R Zhang, J Bergsbaken, S Tierney, S Wallace, D Kushner, E Hartenbach Gynecologic Oncology 176, S59-S60, 2023 | | 2023 |
